Blood and tumor samples from patients previously treated with Bria-IMT™ (from the proof-of-concept clinical trials) have been analyzed using cutting-edge technologies including gene expression analysis, and proteomics (i.e., defined as the large-scale study of the structure and function of proteins). These analyses have provided important insights into understanding which patients are most likely to respond to Bria-IMT™, suggested biomarkers which may indicate response during ongoing therapy, and suggested ways to produce an off-the-shelf personalized immunotherapy which would treat up to 90% of patients with advanced breast cancer (Bria-OTS™).

We are further validating our findings using blood and tumor samples from the patients treated with Bria-IMT™ in the ongoing clinical trials.

Based on the expression of specific biomarkers in the responder vs the non-responder patients, we are characterizing the molecular fingerprint of the patients for which the immunotherapy would be highly effective, and use this fingerprint to develop a companion diagnostic product, called BriaDX™, to identify these patients.

By using BriaDx™ to select the responder patients (i.e. the patients who would most likely benefit from the immunotherapy), and treating them, we expect to improve the likelihood of clinical trial success for Bria-IMT™– to bring hope to thousands of cancer patients with few-to-no treatment options.